Coreline Soft announces Australia launch, new FDA approval

South Korean medical imaging AI company Coreline Soft has made its way to Australia after securing a partnership with a major medical device supplier.

It entered into a strategic partnership with ASX-listed ParagonCare, which aims at major hospitals launching lung cancer screening projects as part of the Australian National Lung Cancer Screening Program in July. The imaging AI provider is known to supply its technology to similar national lung cancer screening programmes in Europe.

Recently, Coreline Soft secured a new supply deal in Europe; it will deliver its AI software to radiology IT solutions provider Xcoorp in Austria.

Meanwhile, the Korean company has obtained a new clearance from the United States Food and Drug Administration for its diagnostic support software for coronary artery disease. 

The 510(k) clearance is for the latest version of AVIEW CAC, an AI-powered solution that enables coronary artery calcification analysis. The software was first approved by the US FDA last year. 

Japan OKs JLK's non-contrast CT stroke AI

Another Korean medical imaging AI company, JLK, has also obtained new regulatory approval. 

The company received clearance for its non-contrast CT stroke AI software from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan's Ministry of Health, Labour and Welfare. The software assists in diagnosing cerebral haemorrhage and cerebral infarction in non-contrast CT images.​

The clearance follows PMDA's approval of two other JLK stroke AI solutions based on CT perfusion images and brain perfusion MRI. JLK is still securing approvals from the Japanese government for the remaining solutions in its stroke AI range. 

Insomnia DTx can lower depression risk among youth: study

A clinical study in Hong Kong and China has demonstrated the use of digital therapeutics for insomnia in reducing depression risks among young people.

Researchers from the Chinese University of Hong Kong Faculty of Medicine and Peking University Sixth Hospital explored the application of digital cognitive behavioural therapy for insomnia among youth dealing with insomnia and depressive symptoms.

Findings, which were published in PLoS Medicine, showed that the DTx improved insomnia and depression at both symptom and disorder levels with users demonstrating a 42% lower incidence of depression compared to the control group. 

Over eight in 10 participants in the intervention group also completed their treatments, suggesting motivation among them to proactively address their mental distress, said Dr Chen Si-jing, the paper's first author and a postdoctoral fellow at CU Medicine Department of Psychiatry. 

King Chulalongkorn Memorial Hospital develops Parkinson's app

King Chulalongkorn Memorial Hospital, together with its operator, the Thai Red Cross Society, developed a mobile application for screening Parkinson's disease.

The Check PD app, available on both iOS and Android devices, allows users over the age of 40 to self-screen for Parkinson's. Running on big data and AI, the app conducts a 25-minute evaluation, which includes tests for finger movements, tremors, balance, and voice.  

The app has around 90% accuracy in detecting Parkinson's, the hospital claimed.